These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23584313)

  • 1. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization.
    Berland DW; Malinoff HL; Weiner MA; Przybylski R
    Am J Ther; 2013; 20(4):316-21. PubMed ID: 23584313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.
    Daitch D; Daitch J; Novinson D; Frey M; Mitnick C; Pergolizzi J
    Pain Med; 2014 Dec; 15(12):2087-94. PubMed ID: 25220043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
    Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
    J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec) in post-traumatic pain.
    Correa-Illanes G; Roa RG; B Piñeros JL; Ferrer FT; Adriasola VR
    Pain Manag; 2014 May; 4(3):181-90. PubMed ID: 24835268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
    Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine transdermal system utilization.
    Wallace L; Kadakia A
    Postgrad Med; 2017 Jan; 129(1):81-86. PubMed ID: 27901359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone.
    Ling W; Hillhouse M; Jenkins J; Miotto K; Torrington M; Chapleo C
    J Addict Med; 2012 Jun; 6(2):118-23. PubMed ID: 22475985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal buprenorphine controls central neuropathic pain.
    Weiner M; Sarantopoulos C; Gordon E
    J Opioid Manag; 2012; 8(6):414-5. PubMed ID: 23264319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
    Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
    J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
    Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
    Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine: Opioid Agonist-Antagonist for Refractory Pain of Sickle Cell Disease Patients During Hematopoietic Stem Cell Transplant, Uncontrolled By Full-Agonist Opioids.
    Sakae M
    J Opioid Manag; 2024; 20(4):B14. PubMed ID: 39321068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study.
    Gallagher AM; Leighton-Scott J; van Staa TP
    Clin Ther; 2009 Aug; 31(8):1707-15. PubMed ID: 19808129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine for chronic pain.
    Calderon R; Copenhaver D
    J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):402-5. PubMed ID: 24245573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.